PDS Biotechnology (NASDAQ:PDSB) Given Buy Rating at HC Wainwright

PDS Biotechnology (NASDAQ:PDSB)‘s stock had its “buy” rating reaffirmed by research analysts at HC Wainwright in a research note issued on Wednesday,Benzinga reports. They currently have a $21.00 target price on the stock.

Other analysts also recently issued reports about the company. StockNews.com downgraded PDS Biotechnology from a “hold” rating to a “sell” rating in a research report on Saturday, November 9th. B. Riley lowered their price objective on PDS Biotechnology from $9.00 to $7.00 and set a “buy” rating on the stock in a research note on Monday, November 25th. Finally, Alliance Global Partners upgraded shares of PDS Biotechnology to a “strong-buy” rating in a research report on Wednesday, August 21st. One research analyst has rated the stock with a sell rating, three have issued a buy rating and one has issued a strong buy rating to the company. According to MarketBeat, PDS Biotechnology presently has an average rating of “Moderate Buy” and a consensus price target of $11.67.

PDS Biotechnology Stock Down 2.8 %

PDSB opened at $1.75 on Wednesday. The company’s 50-day moving average price is $2.61 and its two-hundred day moving average price is $3.03. The company has a quick ratio of 2.84, a current ratio of 2.84 and a debt-to-equity ratio of 0.55. PDS Biotechnology has a twelve month low of $1.53 and a twelve month high of $6.68. The stock has a market cap of $65.47 million, a price-to-earnings ratio of -1.51 and a beta of 1.85.

Institutional Trading of PDS Biotechnology

A number of institutional investors have recently added to or reduced their stakes in PDSB. Tempus Wealth Planning LLC purchased a new position in PDS Biotechnology during the 2nd quarter valued at about $55,000. Ground Swell Capital LLC purchased a new position in PDS Biotechnology during the second quarter valued at approximately $67,000. Point72 Asia Singapore Pte. Ltd. bought a new stake in PDS Biotechnology during the 2nd quarter worth approximately $115,000. Squarepoint Ops LLC purchased a new stake in PDS Biotechnology in the 2nd quarter worth approximately $120,000. Finally, Cubist Systematic Strategies LLC purchased a new stake in PDS Biotechnology in the 2nd quarter worth approximately $146,000. Hedge funds and other institutional investors own 26.84% of the company’s stock.

About PDS Biotechnology

PDS Biotechnology Corporation, a clinical-stage biopharmaceutical company, developing a pipeline of targeted cancer immunotherapies in the United States. The company's lead product candidate is PDS0101 (HPV16), which is in Phase II clinical trial provides a first line treatment for the recurrent/metastatic head and neck cancer, and human papillomavirus associated malignancies.